Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C.
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) will participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference on April 14, 2026 at 12:00 PM EDT.
CEO Dr. Neal Walker and senior leaders will join a fireside chat; a live webcast and archived replay will be available on the company website for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ACRS
On Apr 8, the day this news came out, ACRS closed 5.33% above the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- Conference time
- 12:00 PM EDT
- Scheduled fireside chat on April 14, 2026
- Webcast availability
- 30 days
- Archived webcast available on company website
Historical Context
-
Presented Phase 2a ATI‑2138 ePoster showing rapid, sustained AD improvements.
-
Announced ePoster on ATI‑2138 Phase 2a at 2026 AAD Annual Meeting.
-
Completed enrollment of 109‑patient Phase 2 bosakitug atopic dermatitis trial.
-
Planned fireside chat at Leerink Partners 2026 Global Healthcare Conference.
-
Reported 2025 results, pipeline progress, and cash of $151.4M with runway into H2 2028.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
immuno-inflammatory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.
A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.